Altimmune Q2 Earnings Call Highlights

• How Altimmune Could Grab a Big Chunk of the GLP-1 Market

Chief Medical Officer Dr. Christophe Arbet-Engels said PERFORMA volition beryllium conducted astatine astir 300 sites, with astir one-third successful the U.S. and two-thirds extracurricular the U.S. Altimmune is targeting enrollment astatine the little extremity of an estimated 18- to 24-month scope for studies of this type.

The institution said it has sought to trim screening failures and pathology variability done the proceedings design, including usage of AIM-MASH AI-assisted pathology. Under the process described connected the call, digitized biopsy slides volition beryllium assessed by the AI system, which volition place features and suggest scores for pathologists to review. Pathologists volition stay liable for last scoring nether a consensus-reading process.

→ AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be

• This Small Cap Wealth Management Stock Could Provide Big Returns

Altimmune said patients utilizing GLP-1 therapies astatine antidiabetic doses whitethorn beryllium included successful PERFORMA. However, patients utilizing Rezdiffra volition not beryllium included due to the fact that the institution does not privation to compromise the trial's 52-week biopsy endpoint. The institution besides plans to qualify patients who antecedently did not respond to oregon could not tolerate GLP-1 therapies oregon Rezdiffra.

The institution expects the PERFORMA 52-week information readout successful 2029.

AUD Data Supports Regulatory Planning

→ 3 Dividend Champion Utilities for a Market That Can't Sit Still

Altimmune successful July reported affirmative topline results from the Phase II RECLAIM proceedings successful AUD. Arbet-Engels said the 2.4-milligram dose of pemvidutide met the superior endpoint by reducing dense drinking days by 1.45 per week versus placebo astatine week 24.

The proceedings besides met secondary endpoints that the institution said are recognized by the FDA arsenic imaginable registrational measures. Roughly two-thirds of pemvidutide-treated patients achieved a two-level simplification successful World Health Organization hazard drinking levels, compared with astir one-third of placebo patients. More than doubly arsenic galore pemvidutide patients achieved zero dense drinking days versus placebo, according to the company.